bioxceltherapeutics.com is a domain that was created on 2017-03-22,making it 7 years ago. It has several subdomains, such as ir.bioxceltherapeutics.com , among others.
Discover bioxceltherapeutics.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
HomePage size: 210.019 KB |
Page Load Time: 0.865371 Seconds |
Website IP Address: 20.49.104.33 |
Aratana Therapeutics Investor Overview aratana.investorroom.com |
Jobs at Spark Therapeutics careers.sparktx.com |
Avenue Therapeutics, Inc. (ATXI) ir.avenuetx.com |
Viridian Therapeutics, Inc. - Investors & Media investors.viridiantherapeutics.com |
Clinical Pharmacology and Therapeutics Jobs - American Society for Clinical Pharmacology and Therape careers.ascpt.org |
Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) ir.checkpointtx.com |
Investor Relations | TG Therapeutics, Inc. ir.tgtherapeutics.com |
Revance Therapeutics, Inc. - Investor Relations investors.revance.com |
Investors | PTC Therapeutics, Inc. ir.ptcbio.com |
Acorda Therapeutics Inc - Investors ir.acorda.com |
Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) ir.bioxceltherapeutics.com |
Investors | Flexion Therapeutics, Inc. ir.flexiontherapeutics.com |
Mirati Therapeutics Inc. - Investor & Media Relations ir.mirati.com |
Edgewise Therapeutics, Inc. - Investor investors.edgewisetx.com |
Halozyme Therapeutics, Inc. - Investor ir.halozyme.com |
BioXcel Therapeutics: Investor Relations https://ir.bioxceltherapeutics.com/ |
BioXcel Therapeutics https://www.bioxceltherapeutics.com/ |
Sitemap – BioXcel Therapeutics Inc https://www.bioxceltherapeutics.com/sitemap/ |
Careers – BioXcel Therapeutics Inc https://www.bioxceltherapeutics.com/careers/ |
Home Staging – BioXcel Therapeutics Inc https://bioxceltherapeutics.com/home-staging/ |
Disclaimer – BioXcel Therapeutics Inc https://www.bioxceltherapeutics.com/disclaimer/ |
OnkosXcel Therapeutics https://bioxceltherapeutics.com/onkosxcel-therapeutics/ |
Advisors https://www.bioxceltherapeutics.com/advisors/ |
Overview – BioXcel Therapeutics Inc https://www.bioxceltherapeutics.com/overview/ |
igalmi-pi.pdf https://pi.bioxceltherapeutics.com/ |
A bioxceltherapeutics.com. 3600 IN A 20.49.104.33 |
MX bioxceltherapeutics.com. 600 IN MX 2 mx2-us1.ppe-hosted.com. |
NS bioxceltherapeutics.com. 3600 IN NS ns69.domaincontrol.com. |
TXT bioxceltherapeutics.com. 1800 IN TXT cpgjpgx89sw4t1zvjydh725bvfs3vrwr |
SOA bioxceltherapeutics.com. 3600 IN SOA ns69.domaincontrol.com. dns.jomax.net. 2024031303 28800 7200 604800 600 |
Content-Type: text/html; charset=utf-8 |
Date: Tue, 14 May 2024 21:45:22 GMT |
Server: Apache |
Transfer-Encoding: chunked |
Vary: Accept-Encoding |
Strict-Transport-Security: max-age=63072000; includeSubDomains |
X-Powered-By: PHP/7.4.33 |
Link: https://bioxceltherapeutics.com/wp-json/; rel="https://api.w.org/", https://bioxceltherapeutics.com/wp-json/wp/v2/pages/1317; rel="alternate"; type="application/json", https://bioxceltherapeutics.com/; rel=shortlink |
X-XSS-Protection: 1; mode=block |
X-Frame-Options: SAMEORIGIN |
Content-Security-Policy: "default-src self unsafe-inline https://seal.godaddy.com/images/3/en/siteseal_gd_3_h_d_m.gif data: *.onetrust.com *.google.com *.cookielaw.org *.googletagmanager.com *.googleapis.com *.google-analytics.com *.gstatic.com; script-src self unsafe-inline unsafe-eval https://player.vimeo.com/api/player.js https://seal.godaddy.com data: *.cloudflare.com *.cookielaw.org *.googletagmanager.com; style-src self unsafe-inline data: *.googleapis.com; style-src-elem self unsafe-inline data: *.googleapis.com; frame-src self unsafe-inline https://player.vimeo.com/ https://www.google.com/; img-src self unsafe-inline data: https://secure.gravatar.com/ https://cdn.cookielaw.org/ https://seal.godaddy.com/ https://library.elementor.com/ https://s.w.org/images/", X-Content-Type-Options: nosniff |
Referrer-Policy: same-origin |
Feature-Policy: "geolocation self;" |
charset="utf-8"/ |
content="width=device-width, initial-scale=1" name="viewport"/ |
content="max-image-preview:large" name="robots" |
content="WordPress 6.5.2" name="generator" |
content="Elementor 3.19.2; features: e_optimized_assets_loading, e_optimized_css_loading, additional_custom_breakpoints, block_editor_assets_optimize, e_image_loading_optimization; settings: css_print_method-external, google_font-enabled, font_display-auto" name="generator"/ |
content="/wp-content/uploads/2021/09/favicon-32x32-1.png" name="msapplication-TileImage" |
Ip Country: United States |
City Name: Washington |
Latitude: 38.7095 |
Longitude: -78.1539 |
Investors & Media Contact Us Careers Menu Investors & Media Contact Us CareersOverview Executive Officers Board of Directors Advisors OnkosXcel Therapeutics AI-based Drug Re-innovation Our Products Our Pipeline Patients & Advocacy Expanded Access MenuOverview Executive Officers Board of Directors Advisors OnkosXcel Therapeutics AI-based Drug Re-innovation Our Products Our Pipeline Patients & Advocacy Expanded Access AI-based Drug Re-innovation BioXcel Therapeutics, Inc. is a biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence. Innovative Medicine Backed by the Power of AI BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. Innovative Medicine Backed by the Power of AI BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. Our Approach to Drug Development Optimizes R&D economics Shortens development timelines Increases probability of success Latest News VIEW ALL NEWS May 09, 2024 BioXcel Therapeutics Reports First Quarter 2024 Financial Results VIEW RELEASE Apr 25, 2024 BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 VIEW RELEASE Apr 24, 2024 BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting VIEW RELEASE VIEW ALL NEWS Stock Information BioXcel Therapeutics, Inc. May 14, 2024 04:00 PM MARKET/SYMBOL Nasdaq: BTAI PRICE 2.13 CHANGE -0.055 (-2.52%) EVENTS SIGN UP FOR EMAIL ALERTS Linkedin-in TwitterAI-based Drug Re-innovation Our Products Our Pipeline Patients & AdvocacyAI-based Drug Re-innovation Our Products Our Pipeline Patients & Advocacy Investors & Media Contact Us Careers Investors & Media Contact Us CareersAI-based Drug Re-innovation Our Products Our Pipeline Patients & AdvocacyAI-based Drug Re-innovation Our Products Our Pipeline Patients & Advocacy Investors & Media Contact Us Careers Investors & Media Contact Us Careers IGALMI is a trademark of BioXcel Therapeutics, Inc. All other trademarks are the properties of their respective owners. Copyright © 2024 BioXcel Therapeutics Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap Privacy Policy Disclaimer Sitemap All other trademarks are the properties of their respective owners. Copyright © 2023 BioXcel Therapeutics Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap Privacy Policy Disclaimer Sitemap Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use. Scroll to Top You are about to leave BioXcelTherapeutics.com BioXcel Therapeutics, Inc. is not responsible for the content presented on a third-party website. Continue Cancel You are about to leave BioXcelTherapeutics.com BioXcel Therapeutics, Inc. is not responsible for the content presented on a third-party website. Continue Cancel You are about to leave BioXcelTherapeutics.com BioXcel Therapeutics, Inc. is not responsible for the content presented on a third-party website. Continue Cancel You are about to leave BioXcelTherapeutics.com BioXcel Therapeutics, Inc. is not responsible for the content presented on a third-party website. Continue Cancel Welcome to Bioxcel Medical Affairs Are you a healthcare professional practicing in the United States? Cancel Confirm The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support...
Domain Name: BIOXCELTHERAPEUTICS.COM Registry Domain ID: 2107069920_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2024-03-23T11:02:35Z Creation Date: 2017-03-22T15:24:41Z Registry Expiry Date: 2025-03-22T15:24:41Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS69.DOMAINCONTROL.COM Name Server: NS70.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T21:25:07Z <<<